RE:RE:RE:RE: Takeactionnow, tell them the truth - it’s a gamble....Okay, TAN, your clarification taken. The word “model” as you imply is both conceptual and academic. That has yet to be seen if it works and we as investors are paying hard earned money to find out. I am here, as always, critical but not cynical. Happy investing.
Takeactionnow wrote: Dear Aei, you did not understand my usage of the word "provocative", which was meant in a complimentary sense (to you) of provoking thought, and certainly not in any sense of hostility on your part. ;-)
The "great model" is the whole idea of a high-margin remote medicine application to improving health outcomes while reducing costs, all the while providing additional revenues to doctors (a major selling point), and, of course, anticipated great returns to Reliq. I have actually mentioned my meetings and discussions with Lisa on quite a number of occasions in the past. In fact, I rarely invest in small cap issuers without first meeting with management. This is part of my due diligence. The situation with Reliq is no different than with other companies. I am simply an ordinary investor who carries out very in depth due diligence. There is no connection with the company other than that. Thanks for asking.
Aei773ou wrote: If you feel it provocative then the intention is overblown but not from my side. I am not sure at this point one can conclude it is a “great model” because it is still evolving with practically no end results while the judges are still out there. And based on “your years of discussion with Lisa for many years”. This is new and what else you haven’t said about your connection with the company next time. Sorry, I just have to take your words with a grain of salt. No offence intended.
And by the way every one should review their stand and target price as time goes by.
Takeactionnow wrote: A provocative title, but I'll bite.
Of course, every investment is a gamble to a certain degree. The trick is to be balanced in your approach while respecting one's objectives and risk tolerance. I certainly hope that investors aren't pinning all of their hopes on RHT.V! Execution is the big risk here, meaning that, to be successful, the company has to onboard patients and build revenues.
Apart from the (in my opinion) great business model and strengthened sector (which was already growing rapidly),
Lisa Crossley is a far better leader than most people on this board give her credit for. On what do I base that?
Years of experience evaluating and working with companies and their leadership teams, coupled with many meetings and discussions with Lisa for many years. We all need to make our decisions on these matters, but starting with an evaluation of the business plan and management is critical. By the way, note in the "teeswater sweepstakes" that my December 1, 2020 stock price prediction is one of the lowest, at $0.59.
Aei773ou wrote: For RHT I don’t care how optimistic or pessimistic you are playing this stock is always a gamble. Every one says the pandemic actually is good for the company because people need it. However, the pandemic proves before you see the benefit the adverse effect of decelerating business activities to almost a stop already comes to the surface. On the other hand we have some good cards to start off - the existing contracts. Now we need to hit some more good cards to make a strong hand to win. Time will unfold what other cards(PR) we have at the end.